EGR1 and Alzheimer disease: Taken together, all these findings indicate that inhibition of Egr1 expression or of its protein action may be worth further investigation as an adjuvant treatment strategy for AD, with a greater potential in females than males due to the gender-dependent changes across multiple cell types.